– We are the first company in Europe to develop and implement animal-safe and business-scale technology that uses allogeneic stem cells in therapy. Thanks to the use of allogeneic cells, i.e. one donor and many recipients, we have the opportunity to create drugs that will be available immediately, at the clinic, at the veterinarian – says Łukasz Bzdzion, CEO of Bioceltix – Puls Biznesu.
